Preventive role of genistein in an experimental non-alcoholic steatohepatitis model

J Gastroenterol Hepatol. 2007 Nov;22(11):2009-14. doi: 10.1111/j.1440-1746.2006.04681.x.

Abstract

Background and aim: The aim of the present study was to evaluate the preventive role of genistein, a phytoestrogen with a wide variety of pharmacological effects, in an experimental non-alcoholic steatohepatitis (NASH) model.

Methods: Thirty-six Sprague-Dawley rats were divided into three groups. Group 1 (control) received only a standard rat diet, group 2 (placebo) was given a high fat diet (HFD) plus 0.5 mL/day saline subcutaneously, and group 3 (genistein group) a HFD plus subcutaneous genistein injection at dose of 0.2 mg/kg/day for 6 weeks. All rats were killed after 6 weeks. Serum aminotransferases, tumor necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta, and plasma and liver malondialdehyde (MDA) levels were measured. Additionally, steatosis, ballooning degeneration and inflammation of the liver were examined histopathologically.

Results: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (P < 0.001 for each), plasma and liver tissue MDA and plasma TNF-alpha levels (P < 0.001, <0.001, <0.01, respectively) were found to be higher in the placebo group than in the control group. TGF-beta levels, however, were comparable in the placebo and control groups (P > 0.05). Histopathologically, steatosis, inflammatory cells per mm(2) and ballooning degeneration were significantly higher in the placebo group than in the control group (P < 0.001 for each). Nevertheless, AST and ALT (P < 0.05 for each), plasma and liver tissue MDA (P < 0.05 for each) and plasma TNF-alpha levels (P < 0.001) were significantly decreased in the genistein group compared to the placebo group. Histopathologically, steatosis (P < 0.05), inflammatory cells per mm(2) and ballooning degeneration (P < 0.01 for each) in the genistein group were also significantly lower than in the placebo group.

Conclusions: Genistein, a strong antioxidant agent, significantly decreased the plasma TNF-alpha level and remarkably prevented the emergence of NASH by improving the biochemical and histopathological abnormalities via attenuating oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / pharmacology*
  • Antioxidants / therapeutic use
  • Aspartate Aminotransferases / blood
  • Dietary Fats
  • Disease Models, Animal
  • Fatty Liver / blood
  • Fatty Liver / metabolism
  • Fatty Liver / pathology
  • Fatty Liver / prevention & control*
  • Genistein / pharmacology*
  • Genistein / therapeutic use
  • Hepatitis / blood
  • Hepatitis / metabolism
  • Hepatitis / pathology
  • Hepatitis / prevention & control*
  • Lipid Peroxidation / drug effects
  • Liver / drug effects*
  • Liver / enzymology
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Malondialdehyde / blood
  • Malondialdehyde / metabolism
  • Organ Size
  • Oxidative Stress / drug effects*
  • Rats
  • Rats, Sprague-Dawley
  • Transforming Growth Factor beta / blood
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Dietary Fats
  • Transforming Growth Factor beta
  • Tumor Necrosis Factor-alpha
  • Malondialdehyde
  • Genistein
  • Aspartate Aminotransferases
  • Alanine Transaminase